Celldex Therapeutics, Inc. (NASDAQ:CLDX) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Monday, July 24th.
Several other equities research analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Aegis reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Cowen and Company reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. ValuEngine downgraded shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and an average price target of $7.32.
Celldex Therapeutics (CLDX) traded up 0.82% during trading on Monday, hitting $2.45. 1,486,444 shares of the company were exchanged. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $5.02. The company’s market capitalization is $314.44 million. The company has a 50-day moving average of $2.47 and a 200-day moving average of $3.01.
Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.05. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $1.21 million. Celldex Therapeutics had a negative net margin of 2,233.44% and a negative return on equity of 53.55%. Celldex Therapeutics’s quarterly revenue was up 175.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.32) earnings per share. Analysts forecast that Celldex Therapeutics will post ($1.05) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This report was posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thestockobserver.com/2017/08/12/bidaskclub-lowers-celldex-therapeutics-inc-cldx-to-strong-sell-updated-updated.html.
Hedge funds have recently made changes to their positions in the company. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 6,000 shares in the last quarter. BB&T Securities LLC purchased a new stake in shares of Celldex Therapeutics during the second quarter valued at $117,000. Overbrook Management Corp purchased a new stake in shares of Celldex Therapeutics during the second quarter valued at $139,000. Pacad Investment Ltd. purchased a new stake in shares of Celldex Therapeutics during the second quarter valued at $150,000. Finally, Tudor Investment Corp Et Al boosted its stake in shares of Celldex Therapeutics by 256.6% in the fourth quarter. Tudor Investment Corp Et Al now owns 47,806 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 34,400 shares in the last quarter. 65.83% of the stock is owned by hedge funds and other institutional investors.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.